March 13th 2023
The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Low-Dose CT Screenings Associated With Lung Cancer Overdiagnosis in Nonsmoking Asian Women
January 27th 2022Investigators believe that low-dose CT screenings should only be offered to heavy smokers after identifying an association between the diagnostic and an overdiagnosis in nonsmoking Asian women.
Expert Commentary on the Product Profile of Tepotinib
November 14th 2021In an interview with ONCOLOGY®, David Hughes PharmD, BCOP, and Jessica Freydman, PharmD, offers a comprehensive review of real-world treatment considerations of tepotinib as therapy for patients with metastatic non–small cell lung cancer that have MET exon14 skipping mutations.
Edward B. Garon, MD, Discusses Outcomes in NSCLC With Dato-DXd From TROPION-PanTumor01
October 14th 2021CancerNetwork® sat down with Edward B. Garon, MD, at the 2021 World Conference on Lung Cancer to talk about key findings with datopotamab deruxtecan therapy in patients with non–small cell lung cancer and other ongoing trials.
Alexander Spira, MD, PhD, FACP, Discusses Impacts of COVID-19 at Individual Treatment Facilities
September 25th 2021CancerNetwork® sat down with Alexander Spira, MD, PhD, FACP, at the 2021 World Conference on Lung Cancer to talk about COVID-19 and immediate changes that took place during the pandemic.